Favipiravir vs. COVID-19
RDIF reported positive results of the first clinical trials of Favipiravir
Commercial deliveries of the drug may begin as early as the end of May
The first interim clinical trials of the drug "Favipiravir" in patients hospitalized with COVID-19 showed a positive result, the head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev told reporters.
"According to the data obtained, 60% of patients out of 40 people who took Favipiravir had a negative test for coronavirus after 5 days of therapy, which is 2 times higher than in the standard therapy group. The data coincide with the results of Chinese studies, which also showed a reduction in the duration of the disease from 11 days to 4-5 days," Dmitriev said.
According to him, clinical trials of the drug will be completed by the end of May. At the next stage, the drug is awaiting receipt of a registration certificate for the possibility of its use throughout the country.
"The HimRar Group of Companies together with RDIF may begin commercial deliveries of the drug as early as the end of May. The production facilities and the necessary reagents are prepared. Russia will become one of the few countries in the world that independently produce a coronavirus drug, and will be able to guarantee its reliable supply to medical institutions," Dmitriev said.
Currently, 6 leading medical centers in Moscow, Smolensk and Nizhny Novgorod are participating in clinical trials, including I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University, CCB. In total, the research will cover 330 patients with confirmed coronavirus infection in 30 centers in 8 regions of the Russian Federation.
Portal "Eternal youth" http://vechnayamolodost.ru